Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Effect of intraarticular drug injection in patients with temporomandibular joint disorders with limited mouth opening: a system review and network meta-analysis

Zou S., Yue Y., Wang X., Liu Q.

Meta-analysis on Face & Skin, published in J Oral Facial Pain Headache (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
J Oral Facial Pain Headache (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41436108
PMCID
PMC12727178
DOI
10.22514/jofph.2025.041

Abstract (original English)

Background This network meta-analysis (NMA) aims to evaluate the comparative efficacy of 13 intra-articular pharmacologic interventions in improving maximal mouth opening (MMO), pain relief, and functional recovery in patients with temporomandibular disorders (TMD) and restricted jaw mobility. Methods A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science to identify randomized controlled trials (RCTS) evaluating the effects of 13 intra-articular drug injections in patients with limited mouth opening TMD. The methodological quality of the included studies was assessed using the risk of bias (ROB) tool, and data were independently extracted by two researchers. Primary outcomes included maximum mouth opening (MMO) and pain intensity; secondary outcomes included joint lateral and protrusive movements. Results A total of 38 RCTs involving 1533 TMD patients were included. Thirteen different agents (including HA: hyaluronic acid, PRF: platelet-rich fibrin, PDGF: platelet-derived growth factor, PRP: platelet-rich plasma, MOR: morphine, LA: local anesthetic, MA: micro-fragment fat, TRA: tramadol, SAL: Saline, GC: glucocorticoid, GLU: glucose, NS: non-steroidal, and ARTH: arthrocentesis only) were evaluated. NMA results showed that PRF injection after arthrocentesis significantly improved the maximum temporomandibular joint opening (surfa

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansTemporomandibular Joint DisordersRange of Motion, ArticularInjections, Intra-ArticularRandomized Controlled Trials as Topic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research